Navigation Links
Stiefel Laboratories Appoints First Chief Scientific Officer
Date:4/7/2008

CORAL GABLES, Fla., April 7, 2008 /PRNewswire/ -- Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced Gavin Corcoran, M.D., FACP, has been promoted to the newly created position of chief scientific officer.

Creating the position of chief scientific officer will reinforce the already critical role played by the R&D organization and the unity between all R&D departments. It also will further strengthen the collaboration among Stiefel's five R&D facilities around the world.

As chief scientific officer, Corcoran will oversee global scientific and operational activities related to product development and support; medical and scientific affairs; clinical and pre-clinical research; pharmacovigilance; portfolio planning; and regulatory affairs.

"Gavin's promotion to chief scientific officer is a testament to the wonderful work he has done for Stiefel since he came on board," said Brent Stiefel, executive vice president, Global Corporate Development and Product Portfolio. "We chose Gavin to lead our R&D division because his vast experience along with his keen understanding of the industry arms him with the insight that will improve today's skin treatments and develop tomorrow's solutions."

The accomplishments Stiefel references include Corcoran establishing global R&D headquarters in Research Triangle Park, North Carolina; helping to lead integration following the acquisition of Connetics Corporation; overseeing R&D facilities on four continents; and strengthening the alignment of the R&D objectives and structure with the strategic direction of the business.

Prior to his promotion, Corcoran served as senior vice president, Global Research and Development. He joined Stiefel in 2005 as senior vice president, Global Clinical and Regulatory Affairs and has been a driving force in advancing the expansion of a world-class, global research and development organizati
'/>"/>

SOURCE Stiefel Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Stiefel Laboratories, Inc. Appoints New President
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
4. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
7. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
8. Mesa Laboratories Names New Vice President of Sales and Marketing
9. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
10. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
11. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...
(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...
(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...
(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...
Breaking Medicine News(10 mins):Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3
... marked by Sanofi-Aventis. It is one of the leadin... great trouble as its drug is going to go// off-pa...gs on the market, and more are on the way. This is...ho depend on Ambien for a good night’s sleep. Goo...
...easonal flu vaccine, can offer protection to five ...ers. Though, this is no solace towards arming ones...conducted a study, where injections, one-fifth of ...skin instead of the muscle. This helped in expandi...
... State University have discovered a hitherto unkno...sion of the HIV/AIDS virus. //It was found that tw...also destroy the DNA of the HIV virus, which is vi...cell. The report published in the Proceedings of ...
...ia has shown that making the obese children, who f...o do strenuous exercise will only do more harm tha...ck when you were pregnant?" Wollongong University'...ere are these programmes to help them lose weight,...
Other Medicine News:Health News:Ambien and the Other Insomnia Drugs 2
(Date:8/17/2008)..., Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/...nced that the first pivotal Phase 3,clinical trial...s has,completed enrolment., The first efficacy da...ng the first half of 2009. The trial commenced its...ecruitment target of 250 subjects in June,2008 and...
(Date:8/14/2008)... A Complimentary Continuing Education Activity...alovirus (CMV) is a,significant cause of morbidity... cell transplantation. The clinical manifestations...ntestinal disease to life-threatening,pneumonia, m... order to prevent CMV infection and reduce CMV dru...
(Date:8/14/2008)...ALM BEACH, Fla., Aug. 14 /- The Clini...g aimed at educating physicians,clinical coordina...ts in,clinical trial. It will be held in Boca Rato...cian investigators, clinical coordinators, monitor...ation about how to incorporate,clinical trials int...
(Date:8/13/2008)...s risk managers with comprehensive overview of cli...d required coverage, CHICAGO, Aug. 13 /PRNewswire...gy arm of Aon Corporation (NYSE: AOC ) and the le...ons, today announced it has launched a new,Clinica...-leading,browser-based risk management informatio...
Breaking Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2Aon eSolutions Launches Clinical Trials Module 2Aon eSolutions Launches Clinical Trials Module 3Aon eSolutions Launches Clinical Trials Module 4William R Ringo Joins Hyperion Therapeutics Inc Board of Directors as Chairman 1160 1William R Ringo Joins Hyperion Therapeutics Inc Board of Directors as Chairman 1160 2International team identifies 480 genes that control human cell division 2495 1International team identifies 480 genes that control human cell division 2495 2International team identifies 480 genes that control human cell division 2495 3Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 9196 1EggFusion Helps Retailers Address Consumers Food Safety Concerns 9191 1EggFusion Helps Retailers Address Consumers Food Safety Concerns 9191 2EggFusion Helps Retailers Address Consumers Food Safety Concerns 9191 3
...59th American Academy of Neurology Annual Meeting,...PRNewswire/ --,PTC Therapeutics, Inc. (PTC), a bio...d development of small-molecule drugs targeting,po...ced positive,interim data from a Phase 2 clinical ... dystrophy (DMD) due to a nonsense mutation.,The r...
..., May 4, 2007 – Isotechnika Inc.,(TSX:ISA) a...,ISA247, referred to as LX211 by our partner Lux B...o presentations at the,Association for Research in...eing held May 6-10 in Fort Lauderdale, Florida. , ... May 5 during a,satellite session of the American ...
Other Medicine Technology:PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 5Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 2Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 3Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 4
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli
For the qualitative differential detection of circulating Plasmodium falciparum (P.f) antigen and an antigen that is common to all four species of malaria:plasmodium falciparum (P.f), plasmodium viv
Medicine Products: